ALGS - Company ID 0001799448
Aligos Therapeutics, Inc. trades as ALGS. In its fiscal 2025 annual report the company posted revenue of $2.19M, down 39.5% from the prior year and net income of -$24.19M. This page tracks Aligos Therapeutics, Inc. through 332 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -1416.2% to -1106.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Major company event | 8-K | 2026-04-21 |
The largest companies sharing Aligos Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Aligos Therapeutics, Inc. reported revenue of $2.19M for fiscal year 2025, a decrease of 39.5% year over year.
In its latest fiscal year Aligos Therapeutics, Inc. reported a net loss of $24.19M.